Page last updated: 2024-11-09

dithizone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dithizone: Chelating agent used for heavy metal poisoning and assay. It causes diabetes. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID657262
CHEMBL ID1492000
CHEBI ID177759
SCHEMBL ID29409
SCHEMBL ID4463035
SCHEMBL ID10028276
MeSH IDM0006622

Synonyms (84)

Synonym
1-anilino-3-phenyliminothiourea
CHEBI:177759
AKOS003193919
(1e)-3-anilino-1-phenyliminothiourea
nsc4275
nsc-4275
nsc215189
nsc-215189
(3e)-1-anilino-3-phenylimino-thiourea
diazenecarbothioic acid, phenyl-, 2-phenylhydrazide
formic acid, (phenylazo)thio-, 2-phenylhydrazide
diazenecarbohydrazonothioic acid, n,2-diphenyl-
ai3-52366
thioformic acid, phenylazo-, phenylhydrazide
(phenylazo)thioformic acid, 2-phenylhydrazide
1,5-diphenyl-3-thiocarbazone
einecs 200-454-1
nsc 215189
3-formazanthiol, 1,5-diphenyl-
carbazone, diphenylthio-
wln: rnunyus&mmr
diazenecarbohydrazonothioic acid,2-diphenyl-
1,5-diphenyl-3-mercaptoformazan
3-formazanthiol,5-diphenyl-
dithizon
usaf ek-3092
semicarbazide, 1-phenyl-4-(phenylimino)-3-thio-
dithizone
diphenylthiocarbazone
ditizon
nsc99124
60-10-6
nsc-99124
(phenylazo)thioformic acid 2-phenylhydrazide
diazenecarbothioic acid, 2-phenylhydrazide
dithizone, practical grade
dithizone, acs reagent, >=85.0%
smr000058361
MLS000028397
NCIOPEN2_006427
NCGC00018169-01
dithizone, puriss. p.a., acs reagent, for spectrophotometric det. of cd, cu, hg, pb, zn, >=99.0% (chn)
D0949
A832603
1-phenylazanyl-3-phenylimino-thiourea
NCGC00018169-02
NCGC00018169-03
diazenecarbothioic acid, 2-phenyl-, 2-phenylhydrazide
AKOS024348879
HMS2235C06
STL281381
(e)-n',2-diphenyldiazenecarbothiohydrazide
FT-0606977
1,5-diphenylthiocarbazone
1-(phenylamino)-3-(phenylimino)thiourea
HMS3371I20
CHEMBL1492000
dithizone e-form
unii-njz2cj4d6p
dithizone [mi]
njz2cj4d6p ,
760132-01-2
diphenylthiocarbazone [who-dd]
SCHEMBL29409
D-8750
SCHEMBL4463035
DTXSID0058770
UOFGSWVZMUXXIY-UHFFFAOYSA-N
SCHEMBL10028276
J-610048
STR04412
n',2-diphenyldiazenecarbothiohydrazide #
UOFGSWVZMUXXIY-BMRADRMJSA-N
mfcd00003025
dithizone, puriss. p.a., reag. ph. eur., >=98% (chelatometric), for metal titration
dithizone, jis special grade, >=85.0%
H11950
dithizone, p.a., acs reagent, 98.0%
n',2-diphenyldiazenecarbothiohydrazide
dithizone acs grade
3-mercapto-1,5-diphenylformazan
Q416513
(e)-1,5-diphenylthiocarbazone
n'-anilino-n-phenyliminocarbamimidothioic acid

Research Excerpts

Overview

Dithizone (DTZ) is a recognized diabetogenic agent in vivo. It is a supravital stain commonly used for identification of islets to be used for transplantation.

ExcerptReferenceRelevance
"Dithizone (DTZ) is a selective stain for pancreatic islets which facilitates their identification, being of special interest in human islet isolation assessment. "( Deleterious effect of dithizone-DMSO staining on insulin secretion in rat and human pancreatic islets.
Casamitjana, R; Conget, JI; Gomis, R; González-Clemente, JM; Sarri, Y; Vives, M, 1994
)
2.05
"Dithizone (DTZ) is a recognized diabetogenic agent in vivo, and a supravital stain commonly used for identification of islets to be used for transplantation. "( Staining and in vitro toxicity of dithizone with canine, porcine, and bovine islets.
Borland, KM; Chick, WL; Clark, SA; Rusack, TC; Sherman, SD,
)
1.85

Effects

ExcerptReferenceRelevance
"Dithizone has no effect on the amount of microvasculature, but does impact genes critical to nitric oxide signaling likely contributing to mesenteric vasoconstriction."( Dithizone-induced Paneth cell disruption significantly decreases intestinal perfusion in the murine small intestine.
Berger, JN; Gong, H; Good, M; McElroy, SJ, 2019
)
2.68

Treatment

ExcerptReferenceRelevance
"Dithizone treatment significantly decreased intestinal perfusion compared to controls (p < 0.01). "( Dithizone-induced Paneth cell disruption significantly decreases intestinal perfusion in the murine small intestine.
Berger, JN; Gong, H; Good, M; McElroy, SJ, 2019
)
3.4

Toxicity

ExcerptReferenceRelevance
" The concentration dependence of toxic effects paralleled the concentration dependence of cellular staining."( Staining and in vitro toxicity of dithizone with canine, porcine, and bovine islets.
Borland, KM; Chick, WL; Clark, SA; Rusack, TC; Sherman, SD,
)
0.41

Dosage Studied

ExcerptRelevanceReference
"The determination of islet mass is important for the normalization of islet experiments in the laboratory and for the precise dosing of islets for transplantation."( Areal density measurement is a convenient method for the determination of porcine islet equivalents without counting and sizing individual islets.
Ammon, HP; Becker, HD; Doser, M; Lembert, N; Petersen, P; Wesche, J, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (25)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency19.95260.004023.8416100.0000AID485290
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency25.11890.631035.7641100.0000AID504339
LuciferasePhotinus pyralis (common eastern firefly)Potency19.01150.007215.758889.3584AID588342
Nrf2Homo sapiens (human)Potency12.58930.09208.222223.1093AID624171
ATAD5 protein, partialHomo sapiens (human)Potency18.35640.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency3.12780.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency32.46480.180013.557439.8107AID1460; AID1468
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency19.95260.707912.194339.8107AID720542
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency11.22020.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency10.00000.00137.762544.6684AID914; AID915
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency11.22020.28189.721235.4813AID2326
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency35.48130.707936.904389.1251AID504333
P53Homo sapiens (human)Potency50.11870.07319.685831.6228AID504706
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency10.00000.035520.977089.1251AID504332
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency17.78280.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency15.84890.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency23.10930.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency3.16233.548119.542744.6684AID743266
mitogen-activated protein kinase 1Homo sapiens (human)Potency25.11890.039816.784239.8107AID1454
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency28.18380.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency0.20600.004611.374133.4983AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency8.91250.125912.234435.4813AID1458
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency35.48130.00419.962528.1838AID2675
TAR DNA-binding protein 43Homo sapiens (human)Potency11.22021.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (324)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990177 (54.63)18.7374
1990's40 (12.35)18.2507
2000's35 (10.80)29.6817
2010's59 (18.21)24.3611
2020's13 (4.01)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.13 (24.57)
Research Supply Index5.90 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index77.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (48.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (1.10%)6.00%
Case Studies1 (0.27%)4.05%
Observational0 (0.00%)0.25%
Other360 (98.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]